Diabetes, obesity & metabolismJun 3, 2017

Participant details in the REWIND trial studying weekly dulaglutide and heart health in diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Apr 6, 2026

Abstract

Recruitment of 9901 participants was completed over 2 years for the REWIND trial investigating dulaglutide's effects on cardiovascular outcomes.

Participants included individuals with type 2 diabetes aged 50 years and older, with a mean age of 66 years and 31% having prior cardiovascular disease.
The primary cardiovascular outcome focuses on the first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
Secondary outcomes include microvascular complications, hospitalization for unstable angina, heart failure events, and all-cause mortality.
The mean duration of diabetes among participants was 10 years, and the mean baseline glycated hemoglobin (HbA1c) was 7.3%.
The trial's international scope and demographic diversity may enhance the relevance of its findings to typical middle-aged patients in general practice.

Simplified

The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. Follow-up will continue until the accrual of 1200 confirmed primary outcomes. Recruitment of 9901 participants (mean age 66 years, 46% women) occurred in 370 sites located in 24 countries over a period of 2 years. The mean duration of diabetes was 10 years, mean baseline HbA1c was 7.3%, and 31% had prior cardiovascular disease. The REWIND trial's international scope, high proportion of women, high proportion of people without prior cardiovascular disease and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be directly relevant to the typical middle-aged patient seen in general practice throughout the world.

Full Text

Full text is available at the source.

View Full Text ↗

Participant details in the REWIND trial studying weekly dulaglutide and heart health in diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief